Cognizant will add more than 800 people to its Life Sciences business unit with the acquisition of Cork, Ireland-based Zenith Technologies.
The deal, expected to close in the third quarter of 2019, subject to closing conditions, was announced Tuesday by the Teaneck-based services provider.
Financial terms were not disclosed.
With 16 locations worldwide, including operation hubs in Ireland, Germany, India, Singapore and the U.S., Zenith specializes in the implementation of digital technologies to manage, control and optimize drug and medical device production.
“Industry 4.0 solutions, encompassing Internet of Things (IoT), automation and analytics, are a strategic focus area for Cognizant,” said Brian Humphries, the company’s chief executive officer, in a prepared statement.
Humphries added the deal would allow Cognizant to become a single-source provider of end-to-end smart factory capabilities, a strategic priority for the company.
“Together, we are better positioned to help clients realize information and operational technology convergence in their manufacturing operations, and advance the development of life-saving drugs, biologics, specialized pharmaceuticals and medical devices,” he added.
